The stock of Akorn, Inc. (NASDAQ:AKRX) is a huge mover today! About 306,567 shares traded hands. Akorn, Inc. (NASDAQ:AKRX) has risen 7.62% since March 7, 2016 and is uptrending. It has outperformed by 0.03% the S&P500.
The move comes after 9 months positive chart setup for the $3.53 billion company. It was reported on Oct, 10 by Barchart.com. We have $44.04 PT which if reached, will make NASDAQ:AKRX worth $1.98 billion more.
Akorn, Inc. (NASDAQ:AKRX) Ratings Coverage
Out of 12 analysts covering Akorn Inc (NASDAQ:AKRX), 7 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 58% are positive. Akorn Inc has been the topic of 18 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock of Akorn, Inc. (NASDAQ:AKRX) has “Neutral” rating given on Tuesday, September 29 by Nomura. The firm earned “Overweight” rating on Monday, March 14 by JP Morgan. Jefferies maintained it with “Buy” rating and $35 target price in Wednesday, March 23 report. JMP Securities initiated Akorn, Inc. (NASDAQ:AKRX) on Wednesday, September 9 with “Market Perform” rating. The firm earned “Overweight” rating on Thursday, September 15 by Piperjaffray. WallachBeth Capital maintained Akorn, Inc. (NASDAQ:AKRX) rating on Friday, August 5. WallachBeth Capital has “Buy” rating and $40 price target. The stock of Akorn, Inc. (NASDAQ:AKRX) earned “Market Perform” rating by Leerink Swann on Wednesday, March 16. The stock of Akorn, Inc. (NASDAQ:AKRX) has “Buy” rating given on Wednesday, December 2 by Nomura. The company was initiated on Tuesday, July 21 by Susquehanna. The rating was maintained by William Blair with “Outperform” on Wednesday, March 23.
According to Zacks Investment Research, “Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. They also market ophthalmic surgical instruments and related products. Customers include physicians, optometrists, wholesalers, group purchasing organizations and other pharmaceutical companies. They also provide contract manufacturing services.”
More important recent Akorn, Inc. (NASDAQ:AKRX) news were published by: Fool.com which released: “Why Akorn, Inc. Is Soaring 39% Today” on March 22, 2016, also Fool.com published article titled: “Why Akorn, Inc. Stock Dropped 10% Today”, Fool.com published: “Why Akorn, Inc. Shares Are Popping 14% Today” on May 10, 2016. More interesting news about Akorn, Inc. (NASDAQ:AKRX) was released by: Nasdaq.com and their article: “Akorn Inc Q2 Earnings Rise 41%” with publication date: August 04, 2016.
AKRX Company Profile
Akorn Inc. (Akorn), incorporated on January 20, 1971, together with its subsidiaries, is a specialty pharmaceutical firm that develops, makes and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Firm operates through two divisions: Prescription Pharmaceuticals and the Consumer Health. The Firm is engaged in the development, manufacturing and marketing of generic pharmaceutical products in alternative dosage forms. It is focused on sterile and non-sterile dosage forms including, ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays. The Company’s Akorn Consumer Health division (ACH) markets a portfolio of OTC brands and various formulations of private-label OTC pharmaceutical products. The Company’s OTC brand is TheraTears Therapy for Your Eyes, which is a family of therapeutic eye care products, including dry eye therapy lubricating eye drops, eyelid and eyelash cleansing foam and eye nutrition supplements.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.